Sharekhan

#SharekhanFNA #SharekhanResearch #Q2FY22 Pharma Review; mixed qtr, results driven by strng gwth in India bizz, US g… https://t.co/0ZNFTKdAGn #SharekhanFNA #SharekhanResearch #Q2FY22

#SharekhanFNA #SharekhanResearch retains Buy on #SolaraActivePharma (PT Rs 1615) #Q2FY22 was weak qtr rslts missed… https://t.co/CXVPfcqpSV #SharekhanFNA #SharekhanResearch #SolaraActivePharma #Q2FY22

#SharekhanResearch retains Positive view on #Metropolis (Upside 18%) #Q2FY22 was muted qtr; focus to grow B2C bizz… https://t.co/0ZYlI4C9z8 #SharekhanResearch #Metropolis #Q2FY22

#SharekhanFNA #SharekhanResearch retains Buy rating on #Aurobindo (PT Rs 875) #Q2FY22 was weak qtr; sustained headw… https://t.co/HXdVdjEtPc #SharekhanFNA #SharekhanResearch #Aurobindo #Q2FY22

#SharekhanFNA #SharekhanResearch retains Buy rating on #Divis (PT Rs 5620) #Q2FY22 growth moderates v/s previous qt… https://t.co/Z71h5ETIx1 #SharekhanFNA #SharekhanResearch #Divis #Q2FY22

#SharekhanFNA #SharekhanResearch retain Buy rating on #Cipla (PT Rs 1150) #Q2FY22 healthy qtr, results ahead of est… https://t.co/DanXyypUgt #SharekhanFNA #SharekhanResearch #Cipla #Q2FY22

#SharekhanFNA #SharekhanResearch retains Buy rating on #TorrentPharma (PT Rs3400) #Q2FY22 was a steady qtr; expandi… https://t.co/Sv8FLyXzvU #SharekhanFNA #SharekhanResearch #TorrentPharma #Q2FY22

#SharekhanFNA #SharekhanResearch retains Buy rating on #Biocon(PT Rs 470) #Q2FY22 was healthy qtr; reducing impact… https://t.co/2GLe8j9M4p #SharekhanFNA #SharekhanResearch #Biocon #Q2FY22

#SharekhanFNA #SharekhanResearch retains Buy on #GlandPharma (PT Rs 4400) #Q2FY22 was a strong qtr; expected strong… https://t.co/PMM484uGUG #SharekhanFNA #SharekhanResearch #GlandPharma #Q2FY22